Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Forma Therapeutics Holdings, Inc. - Common Stock (NQ:FMTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 13, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Forma Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 Next >
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease
From Forma Therapeutics, Inc.
Via Business Wire
FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
From Kahn Swick & Foti, LLC
Via Business Wire
FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
From Kahn Swick & Foti, LLC
Via Business Wire
FMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
From Forma Therapeutics
Via Business Wire
Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Announces Appointment of New Executive Team Members
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Present at the Jefferies Healthcare Conference
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
From Forma Therapeutics
Via Business Wire
Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Participate in Upcoming Investor Conferences
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
From Forma Therapeutics Holdings, Inc.
Via Business Wire
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
From Forma Therapeutics Holdings, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.